In attempting to identify drugs that they believe to be hazardous to small children, Koren and
Nachmani rely heavily on subjective and theoretical considerations. The updated list of 'one …

Abstract DPP-4 inhibitors (sitagliptin, saxagliptin, and linagliptin) are approved for the
treatment of diabetes. They are considered safe due to their hyperglycemia dependent …

Abstract Background and Objective Young children may be accidentally exposed to adult
dose forms of medications, some of which can be fatal, even with a single dose. As …

Abstract Background. The dipeptidyl peptidase-4 (DPP-4) inhibitors sitagliptin, saxagliptin,
and linagliptin are approved by the US Food and Drug Administration in the treatment of …

The article by Tomlin et al.[1] in this issue highlights an area that should be of critical
concern for caregivers committed to optimizing pediatric drug therapy. Significant quality …

Every week in the United States, 56% of children younger than age 18 years and 82% of
adults take at least one medication. Nonprescription medications, including acetaminophen …

There is nothing more devastating than losing the life of a young child because of toxicity
caused by the very drug that was supposed to cure or relieve his/her symptoms. Yet, every …

Background Sulfonylureas are the oldest class of oral antidiabetic medications and one of
the classes that can lead to hypoglycemia. In fact, the most common adverse effect of these …

Adverse drug events (ADEs) are a significant safety risk for hospitalized patients. ‍ 1 Medical
centers devote considerable resources to quality and safety initiatives aimed at mitigating …

Over the past 20 years, several legislative initiatives in the United States have resulted in
hundreds of clinical trials assessing the treatment effects of various drugs in children. 1 …